Morgan Stanley’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.4M Sell
2,656,353
-540,540
-17% -$10.8M ﹤0.01% 1982
2025
Q4
$52.1M Buy
3,196,893
+379,651
+13% +$5.74M ﹤0.01% 2037
2025
Q3
$32.9M Sell
2,817,242
-669,713
-19% -$8.73M ﹤0.01% 2399
2025
Q2
$40.4M Buy
3,486,955
+712,864
+26% +$6.5M ﹤0.01% 2122
2025
Q1
$24.2M Sell
2,774,091
-1,151,180
-29% -$14.5M ﹤0.01% 2500
2024
Q4
$56.4M Sell
3,925,271
-2,551,036
-39% -$40.3M ﹤0.01% 1731
2024
Q3
$146M Buy
6,476,307
+702,439
+12% +$14.5M 0.01% 991
2024
Q2
$112M Buy
5,773,868
+609,361
+12% +$16M 0.01% 1101
2024
Q1
$194M Sell
5,164,507
-3,194,323
-38% -$140M 0.02% 811
2023
Q4
$468M Buy
8,358,830
+4,008,780
+92% +$174M 0.02% 703
2023
Q3
$179M Sell
4,350,050
-1,298,035
-23% -$67.5M 0.02% 745
2023
Q2
$315M Sell
5,648,085
-4,872,606
-46% -$264M 0.03% 542
2023
Q1
$587M Buy
10,520,691
+200,995
+2% +$9.39M 0.06% 296
2022
Q4
$376M Sell
10,319,696
-107,676
-1% -$3.52M 0.04% 433
2022
Q3
$297M Buy
10,427,372
+1,530,496
+17% +$58.3M 0.04% 441
2022
Q2
$403M Sell
8,896,876
-404,980
-4% -$21M 0.05% 350
2022
Q1
$708M Buy
9,301,856
+4,443,059
+91% +$389M 0.1% 209
2021
Q4
$724M Sell
4,858,797
-1,216,315
-20% -$186M 0.09% 220
2021
Q3
$884M Buy
6,075,112
+1,747,269
+40% +$300M 0.12% 178
2021
Q2
$847M Buy
4,327,843
+191,777
+5% +$34.7M 0.11% 182
2021
Q1
$749M Sell
4,136,066
-2,570,353
-38% -$444M 0.11% 189
2020
Q4
$950M Sell
6,706,419
-3,000,124
-31% -$435M 0.15% 152
2020
Q3
$1.21B Buy
9,706,543
+1,485,146
+18% +$156M 0.23% 98
2020
Q2
$734M Buy
8,221,397
+3,172,819
+63% +$247M 0.16% 140
2020
Q1
$315M Buy
5,048,578
+3,958,168
+363% +$309M 0.09% 205
2019
Q4
$83.1M Buy
1,090,410
+633,927
+139% +$38.1M 0.02% 680
2019
Q3
$23M Buy
+456,483
New +$25.3M 0.01% 1386

Other funds holding TXG